2024
Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis
Fernández O, Rosales-Chilama M, Sánchez-Hidalgo A, Gómez P, Rebellón-Sánchez D, Regli I, Díaz-Varela M, Tacchini-Cottier F, Saravia N. Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis. PLOS Neglected Tropical Diseases 2024, 18: e0012156. PMID: 38709850, PMCID: PMC11098511, DOI: 10.1371/journal.pntd.0012156.Peer-Reviewed Original ResearchConceptsAssociated with treatment failureTreatment failureHost risk factorsBALB/c miceRisk factorsDrug susceptibilityClinical strainsOutcome of cutaneous leishmaniasisOdds of treatment failureMeglumine antimoniateParasitological response to treatmentLeishmania (Viannia) panamensisSubgroup of patientsAntimicrobial drug susceptibilityResponse to treatmentU937 macrophagesEvaluate drug susceptibilityCutaneous leishmaniasis patientsCutaneous leishmaniasisFailed treatmentPlasma CmaxTherapeutic responseClinical outcomesPatient's lesionsTreatment outcomes
2023
mHealth Monitoring of Treatment of Cutaneous Leishmaniasis Patients: A Community-Based Implementation Study
Cossio A, Bautista-Gomez M, Alexander N, Del Castillo A, del Mar Castro M, Castaño-Grajales P, Gutiérrez-Poloche Y, Zuluaga L, Vargas-Bernal L, Navarro A, Saravia N. mHealth Monitoring of Treatment of Cutaneous Leishmaniasis Patients: A Community-Based Implementation Study. American Journal Of Tropical Medicine And Hygiene 2023, 109: 778-790. PMID: 37640290, PMCID: PMC10551068, DOI: 10.4269/ajtmh.22-0805.Peer-Reviewed Original ResearchConceptsCommunity health leadersProportion of patientsAdverse drug reactionsCutaneous leishmaniasisDrug reactionsTherapeutic responseHealth workersCutaneous leishmaniasis patientsInitiation of treatmentAnti-leishmanial treatmentStandard of careGlobal health problemMobile health strategiesEffectiveness of treatmentPublic health needsLeishmaniasis patientsCare groupTreatment adherenceHealth strategiesMHealth interventionsPatientsHealth problemsHealth needsMHealth strategiesCase identification
2022
Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia
del Mar Castro M, Cossio A, Navas A, Fernandez O, Valderrama L, Cuervo-Pardo L, Marquez-Oñate R, Gómez MA, Saravia NG. Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia. Pathogens 2022, 11: 378. PMID: 35335703, PMCID: PMC8949591, DOI: 10.3390/pathogens11030378.Peer-Reviewed Original ResearchAddition of pentoxifyllinePeripheral blood mononuclear cellsMeglumine antimoniate treatmentPlacebo-controlled trialCutaneous leishmaniasis patientsBlood mononuclear cellsInflammatory gene expressionAntimoniate treatmentOral pentoxifyllineTrial patientsAdverse eventsInflammatory mediatorsMucosal leishmaniasisLeishmaniasis patientsAntimonial treatmentClinical benefitMononuclear cellsStandard treatmentMultiple lesionsTherapeutic failureTherapeutic responseClinical trialsFailure rateStudy groupSingle lesion
2018
Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure–response relationships
Kip AE, del Mar Castro M, Gomez MA, Cossio A, Schellens JHM, Beijnen JH, Saravia NG, Dorlo TPC. Simultaneous population pharmacokinetic modelling of plasma and intracellular PBMC miltefosine concentrations in New World cutaneous leishmaniasis and exploration of exposure–response relationships. Journal Of Antimicrobial Chemotherapy 2018, 73: 2104-2111. PMID: 29757380, PMCID: PMC6251527, DOI: 10.1093/jac/dky143.Peer-Reviewed Original ResearchConceptsExposure-response relationshipProbability of curePopulation PK modelMiltefosine concentrationsDosing simulationsPK targetPK modelNew World cutaneous leishmaniasisPlasma concentration-time curveCutaneous leishmaniasis patientsPopulation pharmacokinetic modelLarge cohort studyPopulation pharmacokinetic modellingConcentration-time curvePlasma concentration ratioDistribution rate constantMiltefosine exposureCohort studyLeishmaniasis patientsPatient populationEffect compartmentCutaneous leishmaniasisDay 1Three-compartment modelPharmacokinetic modelling
2015
Ex Vivo Host and Parasite Response to Antileishmanial Drugs and Immunomodulators
Gonzalez-Fajardo L, Fernández OL, McMahon-Pratt D, Saravia NG. Ex Vivo Host and Parasite Response to Antileishmanial Drugs and Immunomodulators. PLOS Neglected Tropical Diseases 2015, 9: e0003820. PMID: 26024228, PMCID: PMC4449175, DOI: 10.1371/journal.pntd.0003820.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsOutcome of infectionIL-10Meglumine antimoniateIL-13Therapeutic strategiesAntileishmanial drugsTherapeutic responseCytokine secretionInfected peripheral blood mononuclear cellsParasite survivalHuman peripheral blood mononuclear cellsL. panamensis infectionsCutaneous leishmaniasis patientsPro-inflammatory cytokinesBlood mononuclear cellsIL-13 secretionIntracellular parasite survivalAssessment of hostViability of LeishmaniaEfficacy of treatmentPromising therapeutic strategySecretion of TNFInnovative therapeutic strategiesMonocyte-derived macrophages
2014
CD4 T cell activation by B cells in human Leishmania (Viannia)infection
Rodriguez-Pinto D, Saravia NG, McMahon-Pratt D. CD4 T cell activation by B cells in human Leishmania (Viannia)infection. BMC Infectious Diseases 2014, 14: 108. PMID: 24568275, PMCID: PMC3937821, DOI: 10.1186/1471-2334-14-108.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedB-LymphocytesBiotinCD4-Positive T-LymphocytesColombiaFemaleFlow CytometryFluorescein-5-isothiocyanateGene Expression RegulationHumansImmunoglobulin MInterferon-gammaInterleukin-6Leishmania braziliensisLeishmaniasis, CutaneousLeukocytes, MononuclearLymphocyte ActivationMaleMiddle AgedOvalbuminTumor Necrosis Factor-alphaYoung AdultConceptsCD4 T cellsCutaneous leishmaniasis patientsT cellsB cellsLeishmaniasis patientsT cell activationLeishmania antigenImmune responseCell activationT-cell activation parametersSpecific CD4 T cellsEffective adaptive immune responseCD4 T cell activationB-cell activation markersCultures of PBMCUpregulation of CD86Cell activation markersCostimulatory molecule CD86Activation markers CD25Adaptive immune responsesHuman cutaneous leishmaniasisPurified B cellsT cell culturesHuman B cell linesHuman B cells
2006
Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis
Carrillo E, Ahmed S, Goldsmith-Pestana K, Nieto J, Osorio Y, Travi B, Moreno J, McMahon-Pratt D. Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis. Vaccine 2006, 25: 1534-1543. PMID: 17178178, PMCID: PMC2571115, DOI: 10.1016/j.vaccine.2006.10.036.Peer-Reviewed Original ResearchConceptsSoluble Leishmania antigenAmastigote antigensImmune responseAmerican cutaneous leishmaniasis patientsTh1-like immune responseSoluble leishmanial antigenCutaneous leishmaniasis patientsIL-4 mRNAAppropriate immune responseCanine visceral leishmaniasisElicit appropriate immune responsesIdentification of LeishmaniaGeneral vaccinesLeishmanial antigensIL-10Leishmania antigenLeishmaniasis patientsSLA antigensTNF-alphaDisease manifestationsIFN-gammaMurine modelMouse modelVisceral leishmaniasisLeishmania infantum
2004
Leishmanial Amastigote Antigen P‐2 Induces Major Histocompatibility Complex Class II‐Dependent Natural Killer‐Cell Reactivity in Cells from Healthy Donors
Nylén S, Maasho K, McMahon‐Pratt D, Akuffo H. Leishmanial Amastigote Antigen P‐2 Induces Major Histocompatibility Complex Class II‐Dependent Natural Killer‐Cell Reactivity in Cells from Healthy Donors. Scandinavian Journal Of Immunology 2004, 59: 294-304. PMID: 15030581, DOI: 10.1111/j.0300-9475.2004.01388.x.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, ProtozoanCD8-Positive T-LymphocytesFetal BloodHistocompatibility Antigens Class IIHumansInterferon-gammaInterleukin-10Killer Cells, NaturalLeishmaniaLeishmaniasisLymphocyte ActivationProtozoan VaccinesReceptors, IgGReverse Transcriptase Polymerase Chain ReactionRNA, MessengerConceptsHealthy donorsLeishmaniasis patientsAmerican cutaneous leishmaniasis patientsClass IIMajor histocompatibility complex class IIMajor histocompatibility complex classHistocompatibility complex class IIClass II antibodiesCutaneous leishmaniasis patientsInterleukin-10 productionNatural killer cellsProtective immune responseInterferon-gamma productionIFN-gamma responsesMHC class IIHistocompatibility complex classHealthy adult donorsDevelopment of vaccinesAdherent cell populationAmastigote antigensNatural killerKiller cellsCytokine productionCell reactivityLeishmania infection
1998
Leishmania pifanoi Amastigote Antigen P-4: Epitopes Involved in T-Cell Responsiveness in Human Cutaneous Leishmaniasis
Haberer J, Da-Cruz A, Soong L, Oliveira-Neto M, Rivas L, McMahon-Pratt D, Coutinho S. Leishmania pifanoi Amastigote Antigen P-4: Epitopes Involved in T-Cell Responsiveness in Human Cutaneous Leishmaniasis. Infection And Immunity 1998, 66: 3100-3105. PMID: 9632572, PMCID: PMC108319, DOI: 10.1128/iai.66.7.3100-3105.1998.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsTh1-like responseCytokine productionCutaneous leishmaniasisExperimental murine cutaneous leishmaniasisTh1-like immune responseDetectable interleukin-4Leishmaniasis vaccine developmentCutaneous leishmaniasis patientsMurine cutaneous leishmaniasisBlood mononuclear cellsT cell responsivenessGamma interferon productionT cell proliferationIFN-gamma responsesHuman cutaneous leishmaniasisLeishmaniasis patientsMononuclear cellsImmune responseInterleukin-4Proliferative responseWhole parasite homogenatesIFN-gammaEpitope studiesMultiple epitopes
1996
T-Cell Responsiveness of American Cutaneous Leishmaniasis Patients to PurifiedLeishmania pifanoiAmastigote Antigens andLeishmania braziliensisPromastigote Antigens: Immunologic Patterns Associated with Cure
Coutinho S, Oliveira M, Da-Cruz A, De Luca P, Mendonça S, Bertho A, Soong L, McMahon-Pratt D. T-Cell Responsiveness of American Cutaneous Leishmaniasis Patients to PurifiedLeishmania pifanoiAmastigote Antigens andLeishmania braziliensisPromastigote Antigens: Immunologic Patterns Associated with Cure. Experimental Parasitology 1996, 84: 144-155. PMID: 8932764, DOI: 10.1006/expr.1996.0100.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, ProtozoanAntimonyAntiprotozoal AgentsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCells, CulturedCytokinesFemaleHumansInterferon-gammaInterleukin-2Interleukin-4LeishmaniaLeishmania braziliensisLeishmaniasis, CutaneousLymphocyte ActivationMaleMeglumineMeglumine AntimoniateOrganometallic CompoundsT-LymphocytesConceptsT cell responsesEnd of therapyBeneficial T cell responsesCell responsesCytokine productionProliferative responseAmerican cutaneous leishmaniasis patientsType 1 cytokine productionType 2 cytokine productionPeripheral blood mononuclear cellsCutaneous leishmaniasis patientsType 1 cytokinesLymphocyte proliferative responsesBlood mononuclear cellsLow proliferative responseT cell responsivenessMixed type 1T cell stimulationAmerican cutaneous leishmaniasisImmunologic patternActive diseaseReactive CD4Amastigote antigensLeishmaniasis patientsMononuclear cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply